Antibody Testing in Type 1 Diabetes
In patients with suspected type 1 diabetes, order a panel of four islet autoantibodies at diagnosis: GAD65, IA-2, ZnT8, and IAA (only if not yet on insulin), and test only in accredited laboratories with quality control programs. 1, 2
Which Antibodies to Order
The 2025 ADA Standards of Care recommend standardized islet autoantibody testing for classification of diabetes in adults with phenotypic features overlapping with type 1 diabetes, including:
- Younger age at diagnosis (particularly <35 years)
- Unintentional weight loss
- Ketoacidosis presentation
- Short time to insulin requirement
- BMI <25 kg/m²
- Personal or family history of autoimmune disease 1
Order all four antibodies simultaneously rather than sequentially:
- GAD65 antibodies (glutamic acid decarboxylase)
- IA-2 antibodies (insulinoma-associated antigen-2)
- ZnT8 antibodies (zinc transporter 8)
- IAA (insulin autoantibodies) - critical caveat: only interpretable if measured BEFORE insulin therapy begins, as insulin treatment induces antibodies even with human insulin 2
Interpreting Results
Multiple Antibody Positivity
The presence of ≥2 confirmed islet autoantibodies establishes autoimmune type 1 diabetes and indicates risk for progression. 1 This finding:
- Confirms autoimmune etiology
- Justifies referral to specialized centers
- May qualify patients for disease-modifying therapies (e.g., teplizumab) 2
- Allows staging: Stage 1 (normoglycemia), Stage 2 (dysglycemia), or Stage 3 (overt diabetes) 1
Single Antibody Positivity
If only one antibody is positive, repeat the test and measure the other antibodies to define risk more accurately. 2 Single positivity is less specific and found in the general population at low rates 2.
Antibody-Specific Patterns
- GAD65: Most common, persists longer, associated with slower progression 3
- IA-2: More common in younger patients, associated with more rapid β-cell decline and better initial glycemic control paradoxically 4, 5
- ZnT8: Detected in ~25% of type 1 diabetes, more frequent in acute-onset and age ≤10 years, adds 11.7% diagnostic sensitivity in young patients when combined with GAD65/IA-2 6
- IAA: More prevalent in younger children, becomes uninterpretable after insulin initiation 2
Critical Laboratory Requirements
Only use accredited laboratories with established quality control and proficiency testing programs. 2 Interlaboratory variability remains problematic, particularly for IAA 2. Preferred methods:
- Radiobinding assays for GAD65, IA-2, ZnT8
- Radioisotopic displacement method for IAA
- Results reported in standardized units (JDF units for some assays) 2
Common Pitfalls to Avoid
- Do NOT order IAA after insulin therapy has started - results become uninterpretable 2
- Do NOT repeat antibody testing to monitor disease activity in established diabetes - titers do not guide clinical management outside research protocols 2
- Do NOT rely on single antibody testing - the combination of all four antibodies maximizes diagnostic sensitivity, identifying up to 68% of cases versus 34% with older ICA testing alone 4
- Do NOT assume ethnic prevalence patterns exclude diagnosis - while IA-2 is less common in Asian populations, it still occurs and may indicate more aggressive disease 5
Clinical Stratification by Antibody Status
Patients with all three antibodies (GAD65 + IA-2 + ZnT8) demonstrate:
- Younger age at onset
- Higher fasting glucose and HbA1c
- Lower BMI
- More severe insulin deficiency
- Higher prevalence of other autoimmune conditions (e.g., thyroid disease)
This stratification progressively attenuates with two antibodies, one antibody, then none 3.